BENGALURU (Reuters) – Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.
“Nafamostat (has been) identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany,” the company said in a statement https://reut.rs/2BdSD4o.
The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020.
(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Anil D’Silva)
